Can-Fite BioPharma is focused on developing small molecule drugs that target the A3 adenosine receptor (A3AR), which is significantly expressed in inflammatory and cancerous cells while showing low expression in normal cells. This unique expression pattern allows for targeted pharmacological intervention, making A3AR a promising therapeutic target. The company's lead drug candidates, Piclidenoson and Namodenoson, are synthetic agonists that bind with high affinity to A3AR, leading to the modulation of critical signaling pathways such as NF-kB and Wnt. This modulation results in anti-inflammatory and anti-cancer effects, with clinical studies demonstrating their excellent safety profiles and efficacy in treating conditions like psoriasis and liver cancer.

In addition to its lead candidates, Can-Fite is also developing CF602, an allosteric modulator that enhances the natural ligand adenosine's affinity for A3AR in areas with elevated adenosine levels, such as in diseased tissues. This approach further emphasizes the company's commitment to targeted therapies that selectively affect pathological cells while sparing normal cells, thereby minimizing side effects. The research indicates that A3AR not only serves as a therapeutic target but also as a potential biomarker for predicting patient responses to treatment, reinforcing the strategic focus on precision medicine in Can-Fite's drug development pipeline.

Israel

Can-Fite BioPharma Ltd. is an Israeli biopharmaceutical company with fully integrated pharmaceutical discovery and clinical development capabilities. The Company develops small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. Can-Fite develops its products by harnessing its technology platform which is based on the Gi protein associated A3 adenosine receptor (A3AR).

Can-Fite BioPharma

Company Details